Market capitalization | $1.09b |
Enterprise Value | $701.26m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 43.83 |
P/S ratio (TTM) P/S ratio | 68.13 |
P/B ratio (TTM) P/B ratio | 2.98 |
Revenue (TTM) Revenue | $16.00m |
EBIT (operating result TTM) EBIT | $-321.21m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
15 Analysts have issued a Syndax Pharmaceuticals Inc forecast:
15 Analysts have issued a Syndax Pharmaceuticals Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 16 16 |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -321 -321 |
66%
66%
|
EBIT (Operating Income) EBIT | -321 -321 |
66%
66%
|
Net Profit | -297 -297 |
69%
69%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
Head office | United States |
CEO | Michael Metzger |
Employees | 184 |
Founded | 2005 |
Website | www.syndax.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.